Type 1 Diabetes and Regenerative Medicine: The Immunomodulatory Role of Umbilical Cord–Derived Mesenchymal Stem Cells
Treatments By body area Knee & joints Spine, neck & back Hip Shoulder By condition Autoimmune & inflammatory Neurological Diabetes Anti-aging & vitality Every treatment uses the same Passage 3 protocol. View all treatments How it works Your journey Testimonials Pricing About The center The company The stem cells Facilities People & place Dr. Diana Reyes The team About Medellín ENES Book your consultation Message us Treatments + By body area Knee & joints Spine, neck & back Hip Shoulder By condition Autoimmune & inflammatory Neurological Diabetes Anti-aging & vitality View all treatments → How it works Your journey Testimonials Pricing About + The company The stem cells Dr. Diana Reyes The team Facilities About Medellín ENES Book your consultation Message us on WhatsApp Blog · Type 1 diabetes Type 1 diabetes Type 1 diabetes and stem cells: what they may do for you Type 1 diabetes is an immune problem first. How umbilical cord stem cells are studied to calm that attack, what trials found, and what it means for you. 6 min readReviewed with the medical team of Stem Cells Colombia The 30-second version In type 1 diabetes the immune system attacks the cells in the pancreas that make insulin. Stem cells are studied to calm that attack and protect the insulin-making function still left. Trials show better C-peptide and HbA1c, working alongside your insulin. If you live with type 1 diabetes, you already run a small laboratory in your pocket: a sensor, a pump or a pen, and a brain that does carb math before breakfast. The technology has improved enormously, and research now looks at the root of the problem. That problem is the immune system. This post explains what goes wrong in type 1 diabetes, how umbilical cord mesenchymal stem cells are studied to work on it, what the trials actually found, and what that means for you. What is really going wrong in type 1? Type 1 diabetes is an autoimmune disease. For reasons that mix genes and environment, the immune system starts treating the beta cells of the pancreas, the ones that make insulin, as intruders. Immune cells called T cells lead the attack, and over time fewer and fewer beta cells are left. That is different from type 2 diabetes, where the body still makes insulin but the tissues respond to it poorly. In type 1 the issue is supply, and insulin from outside becomes essential. In plain wordsBeta cells the cells in the pancreas that make insulin, the ones the immune system attacks in type 1. What do today’s treatments leave untouched? Pumps, sensors and newer insulins make daily control safer and easier. But they replace the missing hormone; they do not change the immune attack itself. Many people still have some working beta cells, especially in the first years after diagnosis, and protecting what is left is a real goal. In plain wordsC-peptide a marker released with your own insulin. It shows how much insulin your body still makes. How could stem cells help with an immune problem? Think of the immune system in type 1 as a neighborhood watch that has started chasing the mail carrier. Mesenchymal stem cells don’t fire the watch; they are studied for calming it down. They release signals that may: Slow down the overactive T cells Encourage regulatory T cells, the immune system’s peacekeepers Lower inflammatory messengers around the pancreas Help protect the beta cells that are still working Stem Cells Colombia uses only mesenchymal stem cells from Wharton’s jelly, the soft tissue of the umbilical cord. Reviews describe umbilical cord cells as more primitive and more strongly immunomodulatory than adult sources. MythStem cells turn into new insulin-producing cells. Reality: Mesenchymal cells work on the immune system and inflammation, helping protect the beta cells you still have. What have trials found in people? A randomized trial in China gave Wharton’s jelly cells to 29 people with newly diagnosed type 1 diabetes, alongside intensive insulin therapy. Over two years, HbA1c and C-peptide were better in the treated group than with placebo, with no reported side effects. A 2025 umbrella review, pooling 17 systematic reviews and more than 8,000 patients with diabetes, found that in type 1 the therapy improved C-peptide and HbA1c. The safety profile was generally mild. 29 people in the randomized Wharton’s jelly trial in new-onset type 1 So what is the goal? The aim is to protect the function you still have and make your control steadier, alongside your insulin. Results are usually better when some beta cell function remains, which is often the case earlier after diagnosis. And one rule matters more than any other: never change or stop your insulin on your own, and never because of something you read online, including this post. Insulin is essential in type 1, so every change in dose is your doctor’s decision, for your safety. What this means for you Ask your doctor for a recent C-peptide test; it tells you how much of your own insulin remains. Think of this as protecting the insulin your body still makes, alongside your treatment. Keep your endocrinologist in charge of your insulin, before and after any treatment. Where the evidence stands Lab & animal studiesFirst human studiesSeveral clinical trialsStandard of care Human evidence for mesenchymal stem cells in type 1 diabetes comes from randomized trials and pooled reviews. The most rigorous data show better C-peptide and HbA1c, most clearly in recent-onset disease, with a mild safety profile. The disease itself is well described as an immune attack, which is exactly what these cells are studied to calm. Research is growing, and larger, longer trials are building on these results. Long term effects of the implantation of Wharton’s jelly-derived mesenchymal stem cells from the umbilical cord for newly-onset type 1 diabetes mellitus · Endocrine Journal, 2013 Mesenchymal stem cell therapy for diabetes: An umbrella review · Tissue & Cell, 2025 Umbilical cord mesenchymal stem cells: the new gold standard for mesenchymal stem cell-based therapies? · Tissue